Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10
mostly community-derived Endpoint Wound or scar texture Topical timeline Per-clinician Injectable framing Per-clinician Topical timelines are anchored to published trials
Angle the needle so the water runs down the glass side
Key Findings from Preclinical Research Insights from Animal Studies While we always look to human trials for definitive answers, preclinical research offers a powerful window into how a compound works
At Intra-V, we typically offer BPC-157 as a small subcutaneous injection (just under the skin)
Early evidence for the potential efficacy of this route was published in 1999, where 18 patients with B12 deficiency treated exclusively with 712 days of 2 mg of sublingual cobalamin daily had 4 times higher B12 levels compared to pre-treatment, reaching therapeutic ranges ( There have also been further studies comparing treatment outcomes from the sublingual route to the more established IM and oral routes
A 2 mg GHK-Cu dose carries 0.4 mg BPC-157 and 0.4 mg TB-4 because every draw keeps the vials fixed 50/10/10 ratio
